Placeholder Banner

BIO Comments on Proposed Settlement Agreement Between EPA and Philadelphia Energy Solutions on RFS Obligations

March 26, 2018

BIO submitted comments to the U.S. Department of Justice on the proposed Consent Decree and Environmental Settlement Agreement with the United States Bankruptcy Court for the District of Delaware in PES HOLDINGS LLC., ET AL., Civil Action No. 18-10122 (Bankr. D. Del.), IN RE: PES Holdings, LLC., et al., D.J. Ref. No. 90-5-2-1-10993/11.

BIO is greatly concerned by DOJ and the U.S. Environmental Protection Agency’s Settlement Agreement with PES Holdings, LLC and its debtors, including Philadelphia Energy Solutions Refining and Marketing LLC, to resolve a dispute about the obligations and liabilities of PESRM and related parties under the Clean Air Act’s Renewable Fuel Standard program.

The RFS has spurred investment, research and development, and commercialization of advanced and cellulosic biofuels. The RFS has enabled the advanced biofuels industry to make significant investments to meet the requirements of the RFS.

The Settlement Agreement undermines the goals of the RFS by allowing refiners to escape their RIN obligations under the law. The record shows the debtors shirked compliance with the RFS program while paying unwarranted dividends to shareholders.

BIO requests EPA and DOJ reconsider its Settlement Agreement with the debtors and PESRM.

Download Full Comments Below
IN RE PES Holdings LLC. Et Al. D.J. Ref. No. 90-5-2-1-10993 1 - Biotechn...
Comments FIled on the Proposed Settlement Agreement for PES
Discover More
Innovative breakthroughs can secure our nation’s food supply by reducing greenhouse gas emissions throughout agricultural supply chains; strengthening producers’ resiliency to climate change while increasing production; and tackling hunger and…
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…